Aesthetic Medical Partnership Ltd
Stand: N80
- Facial Aesthetics
- Instruments, accessories & materials
- Prevention & Oral Hygiene
- Surgery equipment
)
){kind=logo}
Aesthetic Medical Partnership (AMP) supplies advanced technologies to progressive aesthetic and medical clinics across the UK and Ireland. At the British Dentistry Show we are showcasing OraFusion, a simple, chairside saliva screening system designed to help dental professionals identify patients who may require further investigation for oral cancer risk. The test is fast, non-invasive and easy to integrate into routine appointments. Our focus is practical innovation - technologies that fit into real clinics, support patient care and create meaningful opportunities for practitioners. AMP works closely with clinicians, providing training, support and education so new treatments are introduced safely, confidently and successfully.
Address
26 Sansome WalkWorcester
WR1 1LX
United Kingdom
Contact Exhibitor
-
)
Aesthetic Medical Partnership has launched the BeVigilant™ OraFusion™ System in the UK and Ireland - a salivary biomarker testing platform designed for use in primary care and dental settings.
-
)
The OraFusion System transforms ambiguous visual findings into quantitative data for unparalleled precision planning, removing the professional guesswork often associated with suspicious oral lesions.Using advanced, non-invasive biomarker analysis, the device tests for p16 and EGFR protein markers from a small saliva sample. This dual-biomarker methodology, combined with each patient’s personalised clinical risk profile, enables accurate stratification and removes the guesswork traditionally associated with evaluating suspicious oral lesions.With chairside results in 15 minutes or less, the system delivers an immediate, validated risk outcome: “Monitor” or “Investigate Further”. This allows clinicians to define the next step instantly, avoiding delays linked to external laboratory testing. The result is a smoother clinical workflow, reduced operational cost, and, most importantly, accelerated access to specialist investigation for patients presenting with elevated risk.
.png){kind=logo}
